BJ:
Joe Davie is a hero, David Sachs is a hero...... what's a scientist to do?
I never answered your question directly. Again, I invest in BTRN from the perspective of solid organ transplantation. 507 is, however, lots of the punch in what I regard as leverage. So.....
I can't say that there's an advantage to anti-CD2 over anti-CD40L. There is just too much preclinical data behind CD40L for me to minimize the potential there (BGEN, IDPH, and..... as effector ligand..... IMNX). I've watched it closely, as I had some early, hands-on experience with Randy Noelle's antibody and the results blew me away.
But, conceptually, it's better to intervene in a given, antigen-specific immune response than to immobilize responses in general. If you read this manuscript.... and I'd like to see the results demo'd in the hands of others......... you may be impressed. Rarely will you see such open and shut data. Makes me worry a bit, actually.
J. Immunol. 160: 3797-3804, 1998
Patent coverage extends to any antibody that recognizes the CD2 epitope defined by 507.
Rick |
